论文部分内容阅读
目的:探讨癫痫间患儿奥卡西平活性代谢物10,11一二氢,10-羟基卡马西平(monhydroxycarbazepin,MHD)血药浓度与不良反应、疗效、合并用药的相关性。方法:建立高效液相色谱法测定儿童MHD稳态血药浓度50例次,记录姓名、性别、年龄、体重、药量、不良反应、疗效和合并用药等详细资料并逐一录入数据库,利用SPSS10.0统计软件辅助分析。结果:发生不良反应组与未发生不良反应组、未控制组与控制组间的奥卡西平剂量无显著性差异(P>0.05),但患儿MHD血药浓度均存在显著性差异(P<0.05)。合并用药组比单药组奥卡西平剂量更高(P<0.05),但患儿MHD血药浓度无显著性差异(P=0.784)。患儿服用奥卡西平后个体差异较大。结论:治疗药物监测有助于个体化给药、鉴别诊断和了解不良反应的发生,以便更好地发挥奥卡西平的抗癫痫间作用。
OBJECTIVE: To investigate the correlation between the plasma concentrations of active metabolites oxaliplatin 10,11-dihydro and 10-hydroxycamazepam (MHD) in children with epilepsy and their adverse reactions, efficacy and combination therapy. Methods: The steady-state plasma concentration of MHD in children was determined by HPLC for 50 times. The detailed information such as name, sex, age, body weight, dosage, adverse reactions, curative effect and combination therapy were recorded and entered into the database by SPSS10. 0 statistical software-assisted analysis. Results There was no significant difference in the dosage of oxcarbazepine between the control group and the untreated group (P> 0.05). However, there was a significant difference in the blood levels of MHD between the two groups (P < 0.05). Combination therapy group than the single-dose oxcarbazepine dose (P <0.05), but no significant difference in children with MHD plasma concentration (P = 0.784). Children taking oxcarbazepine larger individual differences. CONCLUSIONS: Therapeutic drug monitoring is helpful for individualized administration, differential diagnosis and understanding of adverse reactions in order to better exert the antiepileptic effect of oxcarbazepine.